NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 15.4% and is now trading at $126.68. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) announced its quarterly earnings data on Tuesday, May, 5th. The medical equipment provider reported ($0.78) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.99) by $0.21. The medical equipment provider earned $87.47 million during the quarter, compared to analysts' expectations of $86.70 million. Nevro had a negative net margin of 21.36% and a negative return on equity of 40.67%. The business's revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.45) EPS. View Nevro's earnings history.

Nevro updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $86.4-86.9 million, compared to the consensus revenue estimate of $96.96 million.

12 Wall Street analysts have issued twelve-month target prices for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they expect Nevro's share price to reach $115.33 in the next year. This suggests that the stock has a possible downside of 9.0%. View analysts' price targets for Nevro.

News articles about NVRO stock have trended negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nevro earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNevro.

Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Novocure (NVCR), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.29%), Fred Alger Management LLC (5.83%), Invesco Ltd. (4.17%), Franklin Resources Inc. (3.64%), Perceptive Advisors LLC (3.21%) and Lord Abbett & CO. LLC (2.28%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick. View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Balyasny Asset Management LLC, ArrowMark Colorado Holdings LLC, Franklin Resources Inc., Federated Hermes Inc., Nuveen Asset Management LLC, Engineers Gate Manager LP, and Invesco Ltd.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick. View insider buying and selling activity for Nevro.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Lord Abbett & CO. LLC, Two Sigma Advisers LP, Castleark Management LLC, Fred Alger Management LLC, Rock Springs Capital Management LP, and Deutsche Bank AG. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $126.68.

Nevro has a market capitalization of $4.31 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]